Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Retinal Disorder Treatment Market Value Growth And Long-Term Outlook
The retinal disorder treatment market has shown significant expansion in recent years. Its valuation is projected to rise from $13.69 billion in 2025 to $14.86 billion in 2026, registering a compound annual growth rate (CAGR) of 8.6%. This past growth can be ascribed to several factors, including the increasing occurrence of age-related macular degeneration, the worldwide rise in the diabetic population, the establishment of more ophthalmology clinics and specialized hospitals, progress in retinal imaging technologies, and better public understanding of retinal conditions.
The retinal disorder treatment market is anticipated to experience substantial expansion over the upcoming years, projected to achieve a valuation of $21.27 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. This expansion during the forecast period is fueled by several factors, including the creation of extended-duration retinal medications, a rise in the approval of innovative biologics and gene therapies, broader availability of eye care in developing regions, increased funding for ophthalmic studies, and a growing need for customized retinal care. Key developments expected during this period involve the increasing adoption of anti-VEGF treatments, a move towards less invasive retinal procedures, a preference for drug formulations that release medication over time, the broader application of combined therapeutic strategies, and a rise in the utilization of tools for monitoring vision at home.
Get A Free Sample Report With In-Depth Market Insights:
Retinal Disorder Treatment Market Industry Drivers: What’s Behind The Revenue Growth?
The future expansion of the retinal disorder treatment market is anticipated to be fueled by the rising incidence of diabetes. Diabetes is a long-term health condition marked by high blood sugar levels, occurring when the body fails to produce sufficient insulin or use it properly. Among individuals with diabetes, diabetic retinopathy stands as the most prevalent retinal condition. This condition arises from damage to the retina’s blood vessels, potentially resulting in hemorrhage, fluid seepage, and the formation of new vascular structures. Treatments for retinal disorders often involve laser technology to seal off leaky blood vessels or eliminate irregular ones. As an illustration, the National Health Service (NHS), a UK government body, reported in June 2024 that in 2023, an extra 549,000 people in England were identified as being at risk of developing type 2 diabetes. This increased the total number of individuals with non-diabetic hyperglycemia, also known as pre-diabetes, recorded by GPs to 3,615,330. This figure demonstrates a substantial rise from the 3,065,825 recorded in 2022. Consequently, the expanding occurrence of diabetes is propelling the growth of the retinal disorder treatment market.
Retinal Disorder Treatment Market Segment Analysis Spotlighting Growth Areas
The retinal disorder treatment market covered in this report is segmented –
1) By Type: Macular Degeneration, Diabetic Retinopathy, Other Types
2) By Dosage Form: Gels, Eye Solutions, Capsules And Tablets, Eye Drops, Ointments
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration
2) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
3) By Other Types: Retinal Detachment, Retinitis Pigmentosa, Uveitis, Other Retinal Disorders
#Retinal Disorder Treatment Market Growth Trends: What’s Shaping The Future Outlook?
Key players in the retinal disorder treatment market are introducing novel products, such as geographic atrophy therapies, to cater to expanded customer bases, enhance sales, and boost revenue. Current therapeutic approaches for geographic atrophy primarily aim to manage symptoms, decelerate the disease’s advancement, and assist individuals in coping with visual impairment. For example, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, announced that IZERVAY had received approval from the U.S. Food and Drug Administration (FDA). IZERVAY, functioning as a new complement C5 inhibitor, is notable as the sole approved treatment for geographic atrophy (GA) that has demonstrated a statistically significant reduction (p<0.01) in the rate of GA progression at the 12-month primary endpoint in two Phase 3 clinical trials. This distinct attribute establishes IZERVAY (avacincaptad pegol intravitreal solution) as an indicated and effective therapy for GA secondary to age-related macular degeneration (AMD).
Retinal Disorder Treatment Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the retinal disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Adverum Biotechnologies Inc., Kodiak Sciences Inc., Acucela Inc., IVERIC bio Inc., Oxurion NV, Graybug Vision Inc., Clearside Biomedical Inc., Ophthotech Corporation, Opthea Limited, PanOptica Inc., ThromboGenics NV
View The Full Retinal Disorder Treatment Market Report:
Retinal Disorder Treatment Market Regional Analysis And Top Geography
North America was the largest region in the retinal disorder treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal disorder treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
